Vantage logo

Zogenix hands GW a win

A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.

Vantage logo

Zogenix’s pain is GW Pharma’s gain

A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.